Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.62 |
| ▸ | CDC7 | O00311 | 3/20 | 0.51 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38657082 | 0.83 | PDPK1 (0.57) | PDPK1CDC7DBF4TSHRLMNA | |
| SCHEMBL4397297 | 0.81 | PDPK1 (0.55) | PDPK1CDC7DBF4TSHRLMNA | |
| SCHEMBL8187698 | 0.80 | PDPK1 (0.53) | PDPK1CDC7DBF4TSHRLMNA | |
| SCHEMBL17165605 | 0.78 | MKNK1 (0.52) | PDPK1CDC7DBF4TSHRLMNA | |
| SCHEMBL2938157 | 0.77 | CDC7 (0.59) | PDPK1CDC7DBF4TSHRLMNA | |
| SCHEMBL284830 | 0.77 | PDPK1 (1.00) | PDPK1CDC7DBF4LMNACDK2 | |
| SCHEMBL1825971 | 0.76 | MGMT (0.70) | CDK2CDK1MGMT | |
| Water SCHEMBL6474310 | 0.75 | PDPK1 (0.96) | PDPK1CDC7DBF4LMNACDK2 | |
| SCHEMBL9621465 | 0.74 | PDPK1 (0.47) | PDPK1CDC7DBF4TSHRLMNA | |
| SCHEMBL5241436 | 0.74 | TSHR (0.54) | PDPK1TSHRLMNABRAFCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5817799-A | 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-10-06 | — | — | US | claimed |
| EP-0540686-B1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1995-08-30 | — | — | EP | claimed |
| EP-1925675-B1 | Process for production of nucleoside compound | MITSUI CHEMICALS INC (JP) | 2010-02-03 | — | — | EP | disclosed |
| EP-1338654-B1 | PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND | MITSUI CHEMICALS INC (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-7381820-B2 | α-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2′-deoxy-2′-fluoro-β-d-arabinonucleoside | YAMASA CORPORATION (JP) | 2008-06-03 | — | — | US | disclosed |
| EP-1178051-B1 | PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE | MITSUI CHEMICALS INC (JP) | 2008-05-28 | — | — | EP | disclosed |
| EP-1925675-A1 | Process for production of nucleoside compound | Mitsui Chemicals, Inc. (JP) | 2008-05-28 | — | — | EP | disclosed |
| EP-1816135-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | Ajinomoto Co., Inc. (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-20070179290-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | AJINOMOTO CO. INC. (JP) | 2007-08-02 | — | — | US | disclosed |
| US-20070135627-A1 | Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside | KOHEL YAMADA, ETAL | 2007-06-14 | — | — | US | disclosed |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20020193314-A1 | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | MITSUI CHEMICALS, INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6403568-B1 | FOR THERAPY OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) | YAMASA CORPORATION (JP) | 2002-06-11 | — | — | US | disclosed |
| US-20020022722-A1 | 4'-C-ethynyl pyrimidine nucleoside compounds | OHRUI HIROSHI (JP) | 2002-02-21 | — | — | US | disclosed |
| EP-1179598-A1 | PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND | Mitsui Chemicals, Inc. (JP) | 2002-02-13 | — | — | EP | disclosed |
| EP-1178051-A2 | PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2002-02-06 | — | — | EP | disclosed |
| US-6333315-B1 | FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-12-25 | — | — | US | disclosed |
| US-6291670-B1 | VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| US-6103707-A | TREATMENT OF HERPES SIMPLEX VIRUS 1 (HSV-1), HERPES SIMPLEX VIRUS 2 (HSV-2), HUMAN CYTOMEGALOVIRUS (HCMV) AND VARICELLA-ZOSTER VIRUS | YAMASA CORPORATION (JP) | 2000-08-15 | — | — | US | disclosed |
| EP-0839813-A1 | 9-(2-DEOXY-2-FLUORO-4-THIO-BETA-D-ARABINOFURANOSYL)PURINE DERIVATIVES | YAMASA CORPORATION (JP) | 1998-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022722-A1 | 4'-C-ethynyl pyrimidine nucleoside compounds | PNP, TYMP, NUDT1 | PDPK1 642/4885CDC7 1047/4885DBF4 806/4885 |
| US-20070179290-A1 | Production method of fluorinated purine nucleoside derivative, intermediate therefor and production method thereof | PNP, NUDT1, ADAR | PDPK1 2149/4885CDC7 2120/4885DBF4 444/4885 |
| US-20020193314-A1 | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | PNP, GALE, MTAP | PDPK1 191/4885CDC7 530/4885DBF4 837/4885 |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | PDPK1 3656/4885CDC7 844/4885DBF4 233/4885 |
| US-20070135627-A1 | Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside | TYMP, PNP, DUT | PDPK1 401/4885CDC7 464/4885DBF4 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.